Elizabeth Glaser Pediatric AIDS Foundation
Elizabeth Glaser Pediatric AIDS Foundation
News Article | May 23, 2017
As Congress and the Administration determine the future of this vital funding, it's important to recognize that each dollar spent by the United States fighting HIV and AIDS has a direct and considerable impact on the daily health and survival of people in need. If EGPAF were required to absorb even a 10% reduction to our annual budget, it would significantly impact those served by our programs – resulting in 56 additional infant HIV infections and 119 additional adult deaths due to HIV each week. These are real consequences for real people. To halt the remarkable progress we've made to date would not only be irresponsible, but could seriously jeopardize active efforts to end AIDS in children by 2020. Since 2000, there has been an astonishing 70 percent decline in the number of new HIV infections in children worldwide, much of that due to America's leadership. However, important work remains. Every day 400 children are newly infected with HIV, and only 49 percent of the 1.8 million children living with HIV have access to the medications they need to stay alive and healthy. The human cost of the cuts in the president's proposed budget will be substantial and should not be underestimated. Sustained commitment, investment, and prioritization are critical to continuing this progress and removing the final hurdles to our goal of ending AIDS in children. We urge Congress to preserve full funding for U.S. foreign assistance programs. About the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) EGPAF is the global leader in the fight against pediatric HIV/ AIDS and has reached more than 26 million women with services to prevent transmission of HIV to their babies. EGPAF is currently supporting activities in 19 countries and more than 5,000 sites to implement prevention, care, and treatment services; to further advance innovative research; and to execute global advocacy activities that bring dramatic change to the lives of millions of women, children, and families worldwide. For more information, visit www.pedaids.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/1-bil-cut-to-hivaids-will-roll-back-progress-threatens-mothers-and-children-300462624.html
Heidari S.,International AIDS Society |
Mofenson L.,U.S. National Institutes of Health |
Cotton M.F.,Stellenbosch University |
Marlink R.,Harvard University |
And 3 more authors.
Journal of Acquired Immune Deficiency Syndromes | Year: 2011
The provision of antiretroviral drugs for the prevention of mother-to-child HIV transmission has been rising sharply in low- and middle-income countries. Changes to the World Health Organization guidelines support further extension of these programs. The result will be a greatly expanded population of HIV-exposed but uninfected children with substantial exposure to antiretroviral drugs, both in utero and while breastfeeding. There are limited data on possible toxicities in this burgeoning population, and the large number of confounding factors limits any conclusions. Although the evidence on birth defects and mitochondrial toxicity remains equivocal, considerable data link protease inhibitors to preterm delivery and low birth-weight. Transient hematologic toxicities are also likely. The drug impact later in life is an open question. Larger and longer cohort studies are necessary to properly balance the risks and benefits of large-scale infant exposure to antiretroviral agents. © 2011 by Lippincott Williams & Wilkins.
Wilson C.M.,University of Alabama at Birmingham |
Wright P.F.,Dartmouth College |
Safrit J.T.,Elizabeth Glaser Pediatric AIDS Foundation |
Rudy B.,New York University
Journal of Acquired Immune Deficiency Syndromes | Year: 2010
Adolescents and youth aged 15-24 are one of the populations most impacted by the global HIV epidemic with an estimated 50% of new infections occurring in this age group. They are thus one of the prime populations for targeting behavioral and biomedical preventions. However, the dynamics of the HIV epidemic in youth vary widely by geographic region and risk behavior profiles. There are also biological and neurodevelopmental considerations that must be considered in the development, testing, and ultimate dissemination of HIV prevention interventions. These concepts are broadly discussed here. © 2010 by Lippincott Williams & Wilkins.
Grundmann N.,Stanford University |
Iliff P.,ZVITAMBO Project |
Stringer J.,Center for Infectious Disease Research in Zambia |
Wilfert C.,Elizabeth Glaser Pediatric AIDS Foundation
Bulletin of the World Health Organization | Year: 2011
Objective To develop a new algorithm for the presumptive diagnosis of severe disease associated with human immunodeficiency virus (HIV) infection in children less than 18 months of age for the purpose of identifying children who require antiretroviral therapy (ART). Methods A conditional probability model was constructed and non-virologic parameters in various combinations were tested in a hypothetical cohort of 1000 children aged 6 weeks, 6 months and 12 months to assess the sensitivity, specificity, and positive and negative predictive values of these algorithms for identifying children in need of ART. The modelled parameters consisted of clinical criteria, rapid HIV antibody testing and CD4+ T-lymphocyte (CD4) count. Findings In children younger than 18 months, the best-performing screening algorithm, consisting of clinical symptoms plus antibody testing plus CD4 count, showed a sensitivity ranging from 71% to 80% and a specificity ranging from 92% to 99%. Positive and negative predictive values were between 61% and 97% and between 95% and 96%, respectively. In the absence of virologic tests, this alternate algorithm for the presumptive diagnosis of severe HIV disease makes it possible to correctly initiate ART in 91% to 98% of HIV-positive children who are at highest risk of dying. Conclusion The algorithms presented in this paper have better sensitivity and specificity than clinical parameters, with or without rapid HIV testing, for the presumptive diagnosis of severe disease in HIV-positive children less than 18 months of age. If implemented, they can increase the number of HIV-positive children successfully initiated on ART.
Ghanotakis E.,Elizabeth Glaser Pediatric AIDS Foundation |
Miller L.,Elizabeth Glaser Pediatric AIDS Foundation |
Spensley A.,Elizabeth Glaser Pediatric AIDS Foundation
Bulletin of the World Health Organization | Year: 2012
The World Health Organization (WHO) revised its global recommendations on treating pregnant women infected with the human immunodeficiency virus (HIV) with antiretrovirals and preventing mother-to-child transmission (PMTCT) of HIV. Initial draft recommendations issued in November 2009 were followed by a full revised guideline in July 2010. The 2010 recommendations on PMTCT have important implications in terms of planning, human capacity and resources. Ministries of health therefore had to adapt their national guidelines to reflect the 2010 PMTCT recommendations, and the Elizabeth Glaser Pediatric AIDS Foundation tracked the adaptation process in the 14 countries where it provides technical support. In doing so it sought to understand common issues, challenges, and the decisions reached and to properly target its technical assistance. In 2010, countries revised their national guidelines in accordance with WHO's most recent PMTCT recommendations faster than in 2006; all 14 countries included in this analysis formally conducted the revision within 15 months of the 2010 PMTCT recommendations' release. Governments used various processes and fora to make decisions throughout the adaptation process; they considered factors such as feasibility, health delivery infrastructure, compatibility with 2006 WHO guidelines, equity and cost. Challenges arose; in some cases the new recommendations were implemented before being formally adapted into national guidelines and no direct guidance was available in various technical areas. As future PMTCT guidelines are developed, WHO, implementing partners and other stakeholders can use the information in this paper to plan their support to ministries of health.
Gloyd S.,University of Washington |
Wagenaar B.H.,University of Washington |
Woelk G.B.,Elizabeth Glaser Pediatric AIDS Foundation |
Kalibala S.,HIVCore Population Council
Journal of the International AIDS Society | Year: 2016
Introduction: HIV programme data from routine health information systems (RHIS) and personal health information (PHI) provide ample opportunities for secondary data analysis. However, these data pose unique opportunities and challenges for use in health system monitoring, along with process and impact evaluations. Methods: Analyses focused on retrospective case reviews of four of the HIV-related studies published in this JIAS supplement. We identify specific opportunities and challenges with respect to the secondary analysis of RHIS and PHI data. Results: Challenges working with both HIV-related RHIS and PHI included missing, inconsistent and implausible data; rapidly changing indicators; systematic differences in the utilization of services; and patient linkages over time and different data sources. Specific challenges among RHIS data included numerous registries and indicators, inconsistent data entry, gaps in data transmission, duplicate registry of information, numerator-denominator incompatibility and infrequent use of data for decision-making. Challenges specific to PHI included the time burden for busy providers, the culture of lax charting, overflowing archives for paper charts and infrequent chart review. Conclusions: Many of the challenges that undermine effective use of RHIS and PHI data for analyses are related to the processes and context of collecting the data, excessive data requirements, lack of knowledge of the purpose of data and the limited use of data among those generating the data. Recommendations include simplifying data sources, analysis and reporting; conducting systematic data quality audits; enhancing the use of data for decision-making; promoting routine chart review linked with simple patient tracking systems; and encouraging open access to RHIS and PHI data for increased use. Copyright: © 2016 Gloyd S et al.
Strasser S.,Elizabeth Glaser Pediatric AIDS Foundation
Journal of acquired immune deficiency syndromes (1999) | Year: 2012
Given that integration of syphilis testing into prevention of mother-to-child transmission of HIV (PMTCT) programs can prevent adverse pregnancy outcomes, this study assessed feasibility and acceptability of introducing rapid syphilis testing (RST) into PMTCT services. RST was introduced into PMTCT programs in Zambia and Uganda. Using a pre-post intervention design, HIV and syphilis testing and treatment rates during the intervention were compared with baseline. In Zambia, comparing baseline and intervention, 12,761 of 15,967 (79.9%) and 11,460 of 11,985 (95.6%) first-time antenatal care (ANC) attendees were tested for syphilis (P < 0.0001), 523 of 12,761 (4.1%) and 1050 of 11,460 (9.2%) women tested positive (P < 0.0001); and 267 of 523 (51.1%) and 1000 of 1050 (95.2%) syphilis-positive women were treated (P < 0.0001), respectively. Comparing baseline and intervention, 7479 of 7830 (95.5%) and 11,151 of 11,409 (97.7%) of ANC attendees were tested for HIV (P < 0.0001) and 1303 of 1326 (98.3%) and 2036 of 2034 (100.1%) of those testing positive received combination antiretroviral drugs or single-dose nevirapine prophylaxis (P < 0.0001). In Uganda, 13,131 of 14,540 (90.3%) women were tested for syphilis during intervention, with 690 of 13,131 (5.3%) positive and 715 of 690 (103.6%) treated. Syphilis baseline data were collected, but not included in analysis, as ANC syphilis testing before the study was not consistently practiced. Comparing baseline and intervention, 6479 of 6776 (95.6%) and 11,192 of 11,610 (96.4%) ANC attendees were tested for HIV (P = 0.0009) and 570 of 726 (78.5%) and 964 of 1153 (83.6%) received combination or single-dose prophylaxis (P = 0.007). In Zambia, 254 of 1050 (24.2%) syphilis-positive pregnant women were HIV-positive and 99 of 690 (14.3%) in Uganda. Integrating RST in PMTCT programs increases screening and treatment for syphilis among HIV-positive pregnant women and does not compromise HIV services.
Simonds R.J.,Elizabeth Glaser Pediatric AIDS Foundation |
Carrino C.A.,Joint United Nations Programme on HIV AIDS |
Moloney-Kitts M.,Joint United Nations Programme on HIV AIDS
Health Affairs | Year: 2012
In its first five years, the President's Emergency Plan for AIDS Relief (PEPFAR)-the largest commitment ever by any nation to combat a single disease-succeeded in getting 2.1 million people on antiretroviral treatment and 10.1 million people in care; prevented an estimated 237,600 HIV infections in infants; and saved an estimated 3.28 million adult years of life. Much of the global program's success can be attributed to early decisions to implement new structures and approaches designed to meet its ambitious targets quickly, overcome bureaucratic inertia, and ensure continued progress. A unified US government program was created with a single coordinator. There was a focus on quick ramp-up, strategic partnerships, and sustainable local ownership. Accountability and performance were emphasized. These new approaches played critical roles in translating the unprecedented resources and political support for PEPFAR into improved health for millions of people. Successful aspects of the way in which PEPFAR was organized and implemented, along with less successful or deficient ones, offer lessons for any large, complex international health initiative. © 2012 Project HOPE-The People-to-People Health Foundation, Inc.
Wilfert C.M.,Elizabeth Glaser Pediatric AIDS Foundation
Advances in Experimental Medicine and Biology | Year: 2011
Prevention of vertical (i.e., mother-to-child) transmission of HIV is essential to reduce significant HIV-related child morbidity and mortality in developing countries. Globally, pediatric infections comprise about 15% of all new HIV infections each year and virtually all pediatric infections can be prevented by eliminating vertical transmission . The World Health Organization (WHO) recommendations (revised in 2006) for prevention of mother-to-child transmission (PMTCT) 1 include a four-pronged comprehensive strategy . Although we acknowledge the critical role that all approaches play in reducing pediatric HIV infection, the focus of this chapter is on strategies that address the third prong: preventing HIV transmission from infected mothers to their infants. Considerable achievements have been made on this front, including many clinical trials demonstrating good efficacy. © 2011 Springer Science+Business Media, LLC.
Ghanotakis E.,Elizabeth Glaser Pediatric AIDS Foundation |
Wilcher R.,FHI 360
Journal of the International AIDS Society | Year: 2012
Issues: The recently launched ''Global Plan towards the Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive'' sets forth ambitious targets that will require more widespread implementation of comprehensive prevention of vertical HIV transmission (PMTCT) programmes. As PMTCT policymakers and implementers work toward these new goals, increased attention must be paid to the role that gender inequality plays in limiting PMTCT programmatic progress. Description: A growing body of evidence suggests that gender inequality, including gender-based violence, is a key obstacle to better outcomes related to all four components of a comprehensive PMTCT programme. Gender inequality affects the ability of women and girls to protect themselves from HIV, prevent unintended pregnancies and access and continue to use HIV prevention, care and treatment services. Lessons Learned: In light of this evidence, global health donors and international bodies increasingly recognize that it is critical to address the gender disparities that put women and children at increased risk of HIV and impede their access to care. The current policy environment provides unprecedented opportunities for PMTCT implementers to integrate efforts to address gender inequality with efforts to expand access to clinical interventions for preventing vertical HIV transmission. Effective community- and facility-based strategies to transform harmful gender norms and mitigate the impacts of gender inequality on HIV-related outcomes are emerging. PMTCT programmes must embrace these strategies and expand beyond the traditional focus of delivering ARV prophylaxis to pregnant women living with HIV. Without greater implementation of comprehensive, gender transformative PMTCT programmes, elimination of vertical transmission of HIV will remain elusive. Copyright: © 2012 Ghanotakis E et al; licensee International AIDS Society.